ClinicalTrials.gg
CompletedNCT02988882Updated Oct 12, 2020Results posted

OTX-15-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis

A Phase 3 interventional study of Dexamethasone and Placebo Vehicle in Chronic Allergic Conjunctivitis, sponsored by Ocular Therapeutix, Inc.. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-12.

Sponsored by Ocular Therapeutix, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objective of the study was to evaluate the efficacy and safety of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of chronic allergic conjunctivitis

02

Conditions studied

  • Chronic Allergic Conjunctivitis
03

In context

Conjunctivitis, Allergic

211 studies on the registry are indexed under Conjunctivitis, Allergic; 19 are open to participants now.

This study's enrollment of 86 is close to the median of 87 across 175 interventional studies indexed under Conjunctivitis, Allergic.

Browse Conjunctivitis, Allergic studies →

Lead sponsor

Ocular Therapeutix, Inc. is the lead sponsor of 33 studies on the registry; 2 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a positive history of ocular allergies and a positive skin test reaction to a perennial allergen and a seasonal allergen
  • Has a positive bilateral CAC reaction to a perennial allergen within minutes of instillation

Exclusion criteria

Exclusion Criteria:

  • History of refractive surgery (including LASIK procedures) within the past 2 years
  • History of retinal detachment, diabetic retinopathy, or active retinal disease
  • Presence of an active ocular infection or positive history of an ocular herpetic infection at any visit
  • Use any of the disallowed medications during the period indicated
  • History of IOP increase as a result of treatment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    OTX-DP

    OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use

    Drug: Dexamethasone

  • Placebo comparator
    PV

    PV (placebo drug delivery vehicle)

    Other: Placebo Vehicle

Interventions

06

What researchers measure

Primary outcomes

  1. Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6

    Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=No itching

    Time frame: 3 minutes

  2. Ocular Itching Post-CAC (Conjunctival Allergan Challenge) at Visit 6

    Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=No itching

    Time frame: 5 minutes

  3. Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6

    Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=No itching

    Time frame: 7 minutes

07

Results

Posted Apr 30, 2018

Participant flow

Participant flow — Overall Study
MilestoneOTX-DPPlacebo Vehicle
Started4442
Completed4140
Not completed32

Outcome measures

PrimaryOcular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6

Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=No itching

Time frame:
3 minutes
Reported as:
Mean · units on a scale
Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6
units on a scaleOTX-DPPlacebo Vehicle
Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 62.04 ± 1.0882.31 ± 1.115
PrimaryOcular Itching Post-CAC (Conjunctival Allergan Challenge) at Visit 6

Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=No itching

Time frame:
5 minutes
Reported as:
Mean · units on a scale
Ocular Itching Post-CAC (Conjunctival Allergan Challenge) at Visit 6
units on a scaleOTX-DPPlacebo Vehicle
Ocular Itching Post-CAC (Conjunctival Allergan Challenge) at Visit 62.07 ± 1.1002.41 ± 1.039
PrimaryOcular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6

Modified CAC model (Ora, Andover, MA); Grade 0-4, allowing half unit increments; 0=No itching

Time frame:
7 minutes
Reported as:
Mean · units on a scale
Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 6
units on a scaleOTX-DPPlacebo Vehicle
Ocular Itching Post-CAC (Conjunctival Allergen Challenge) at Visit 62.02 ± 1.1312.37 ± 1.129

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OTX-DP0/41 (0%)0/41 (0%)6/41 (14.6%)
Placebo Vehicle0/40 (0%)0/40 (0%)11/40 (27.5%)
Most frequent other events
Most frequent other events
EventOTX-DPPlacebo Vehicle
Adverse EventsGeneral disorders6/4111/40

Baseline characteristics

Age, Continuous
Age, Continuous(years)OTX-DPPlacebo VehicleTotal
Mean39.1 (20 to 68)42.2 (18 to 70)40 (18 to 70)
Sex: Female, Male
Sex: Female, Male(Participants)OTX-DPPlacebo VehicleTotal
Female262551
Male181735
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)OTX-DPPlacebo VehicleTotal
Hispanic or Latino111021
Not Hispanic or Latino333265
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)OTX-DPPlacebo VehicleTotal
American Indian or Alaska Native000
Asian202
Native Hawaiian or Other Pacific Islander000
Black or African American729
White354075
More than one race000
Unknown or Not Reported000
Iris Color
Iris Color(Participants)OTX-DPPlacebo VehicleTotal
Black101
Blue61521
Brown241943
Hazel538
Green8513
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2015, a primary completion of Apr 2016 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2018, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2016
First posted
Dec 9, 2016
Start
Jun 2015
Primary completionActual
Apr 27, 2016
CompletionActual
Apr 27, 2016
Results first posted
Apr 30, 2018
Last update
Oct 12, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02988882
Collaborators
ORA, Inc.
Responsible party
Sponsor
First posted
Dec 9, 2016
Start date
Jun 2015
Primary completion
Apr 27, 2016
Completion
Apr 27, 2016
Results posted
Apr 30, 2018
Last update
Oct 12, 2020
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion